Your browser doesn't support javascript.
loading
Treatment progress of relapsed/refractory follicular lymphoma / 白血病·淋巴瘤
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-988956
Responsible library: WPRO
ABSTRACT
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. The outcome of relapsed/refractory FL patients after multi-therapy is poor. The 64th American Society of Hematology annual meeting in 2022 announced the latest updates on relapsed/refractory FL, including targeted therapy, bio-specific antibodies and chimeric antigen receptor T-cell. This review provides an overview of these updates.

Full text: Available Database: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Leukemia & Lymphoma Year: 2023 Document type: Article
Full text: Available Database: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Leukemia & Lymphoma Year: 2023 Document type: Article
...